1375 results
Type of content
News Remove News filter
-
List item
News: European Medicines Agency revises MUMS / limited-market policy
CVMP, Last updated: 18/06/2013Medicines Agency revises MUMS / limited-market policy … minor-use-minor-species (MUMS) / limited-market policy (MUMS policy) for … applications for products for limited markets is intended to stimulate … -
List item
Press release: Wyeth Europa Limited withdraws its marketing authorisation application for Brilence
Last updated: 28/05/2010Wyeth Europa Limited withdraws its marketing authorisation … notified by Wyeth Europa Limited of its decision to withdraw … 21-24 June 2010. Wyeth Europa Limited withdraws its marketing authorisation … -
List item
Press release: La Jolla Limited withdraws its marketing authorisation application for Riquent
Last updated: 13/10/2006La Jolla Limited withdraws its marketing authorisation … formally notified by La Jolla Limited of its decision to withdraw … PRESS RELEASE La Jolla Limited withdraws its marketing authorisation … -
List item
Press release: Four-week limit for use of high-strength estradiol creams
PRAC, Last updated: 04/10/2019Four-week limit for use of high-strength … committee (PRAC) has recommended limiting the use of high-strength … size of the tube will be limited to 25 grams to prevent use … -
List item
News: New medicine for multiple myeloma patients with limited treatment options
Last updated: 22/07/2022multiple myeloma patients with limited treatment options … multiple myeloma patients with limited treatment options … -
List item
News: Changes to submission and assessment of maximum residue limits of veterinary medicines in foods
Last updated: 07/06/2018assessment of maximum residue limits of veterinary medicines in … assessment of maximum residue limits (MRLs) of veterinary medicines … use or minor species (MUMS)/limited market will be revised to … -
List item
News: Policy on veterinary medicines for minor use, minor species / limited market revised
CVMP, Last updated: 16/09/2014minor use, minor species / limited market revised … minor-use-minor-species (MUMS) / limited-market policy for veterinary medicines … classified as intended for MUMS/limited market: reduced data requirements … -
List item
Press release: European Medicines Agency recommends limiting long-term use of calcitonin medicines
CHMP, Last updated: 20/07/2012Medicines Agency recommends limiting long-term use of calcitonin … Medicines Agency recommends limiting long-term use of calcitonin … Medicines Agency recommends limiting long- term use of calcitonin … -
List item
Press release: Celgene Europe Limited withdraws its application for an extension of the indication for Revlimid (lenalidomide)
Last updated: 21/06/2012Celgene Europe Limited withdraws its application … Celgene Europe Limited withdraws its application … release Celgene Europe Limited withdraws its application … -
List item
Press release: RepliGen Europe Limited withdraws its marketing authorisation application for SecreFlo (secretin human)
Last updated: 14/09/2012RepliGen Europe Limited withdraws its marketing authorisation … notified by RepliGen Europe Limited of its decision to withdraw … release RepliGen Europe Limited withdraws its marketing authorisation … -
List item
Press release: Alkermes Pharma Ireland Limited withdraws its marketing authorisation application for Megestrol Alkermes (megestrol)
Last updated: 13/03/2012Alkermes Pharma Ireland Limited withdraws its marketing authorisation … by Alkermes Pharma Ireland Limited of its decision to withdraw … Alkermes Pharma Ireland Limited withdraws its marketing authorisation … -
List item
Press release: Pfizer Limited withdraws its application for an extension of the indication for Macugen (pegaptanib sodium)
Last updated: 19/07/2011Pfizer Limited withdraws its application … formally notified by Pfizer Limited of its decision to withdraw … injection. On 14 June 2010, Pfizer Limited submitted an application … -
List item
Press release: Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa (briakinumab)
Last updated: 17/01/2011Abbott Laboratories Limited withdraws its marketing authorisation … Abbott Laboratories Limited withdraws its marketing authorisation … release Abbott Laboratories Limited withdraws its marketing authorisation … -
List item
Press release: Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine)
Last updated: 17/02/2011Merck Serono Europe Limited withdraws its marketing authorisation … notified by Merck Serono Europe Limited of its decision to withdraw … release Merck Serono Europe Limited withdraws its marketing authorisation … -
List item
Press release: Antigenics Therapeutics Limited withdraws its marketing authorisation application for Oncophage (vitespen)
Last updated: 02/12/2009Antigenics Therapeutics Limited withdraws its marketing authorisation … by Antigenics Therapeutics Limited of its decision to withdraw … Antigenics Therapeutics Limited withdraws its marketing authorisation … -
List item
Press release: Gendux Molecular Limited withdraws its marketing authorisation application for Contusugene ladenovec Gendux (contusugene ladenovec)
Last updated: 23/07/2009Gendux Molecular Limited withdraws its marketing authorisation … notified by Gendux Molecular Limited of its decision to withdraw … later stage. Gendux Molecular Limited withdraws its marketing authorisation … -
List item
Press release: Gendux Molecular Limited withdraws its marketing authorisation application for Advexin (contusugene ladenovec)
Last updated: 19/12/2008Gendux Molecular Limited withdraws its marketing authorisation … notified by Gendux Molecular Limited of its decision to withdraw … RELEASE Gendux Molecular Limited withdraws its marketing authorisation … -
List item
Press release: Celgene Europe Limited withdraws its marketing authorisation application for Lenalidomide Celgene Europe (lenalidomide)
Last updated: 04/06/2008Celgene Europe Limited withdraws its marketing authorisation … notified by Celgene Europe Limited of its decision to withdraw … RELEASE Celgene Europe Limited withdraws its marketing authorisation … -
List item
Press release: PRAC confirms four-week limit for use of high-strength estradiol creams
PRAC, Last updated: 17/01/2020PRAC confirms four-week limit for use of high-strength … confirmed its recommendation to limit the use of high-strength … cancer. In addition, there are limited safety data on long term … -
List item
News: First antibody-drug conjugate for multiple myeloma patients with limited treatment options
CHMP, Last updated: 24/07/2020multiple myeloma patients with limited treatment options … multiple myeloma patients with limited treatment options … -
List item
News: Revised guidelines to encourage development of veterinary medicines for minor uses and minor species
CVMP, Last updated: 21/04/2017minor-use-minor-species/ limited-market … or minor species (MUMS)/limited market Adopted by CVMP … minor use or minor species / limited markets (EMA/CVMP/IWP/123243/2006-Rev.2 … -
List item
News: Ten years of MUMS: 22 new veterinary medicines authorised for minor uses and minor species
Last updated: 25/03/2020largely the result of the MUMS/limited market policy for the classification … -
List item
Press release: Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 6-8 October 2015
CVMP, Last updated: 09/10/2015from Eli Lilly and Company Limited, a veterinary medicinal product … from Eli Lilly and Company Limited, a veterinary medicinal product … Pharmaceuticals Manufacturing Limited, to add a new pharmaceutical … -
List item
Press release: Committee for Medicinal Products for Veterinary Use (CVMP): Meeting of 11-13 January 2011
CVMP, Last updated: 14/01/2011from Pfizer Limited, a vaccine for the active … ZULVAC 1+8 Ovis from Pfizer Limited, a vaccine for the active … authorisation. Maximum Residue Limits The Committee adopted … -
List item
Press release: Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 10-12 September 2013
CVMP, Last updated: 13/09/2013from Eli Lilly and Company Limited concerning the addition of … from Eli Lilly and Company Limited concerning the addition of … authorisations. Maximum Residue Limits Further to the adoption …